Fmr LLC Puma Biotechnology, Inc. Transaction History

Fmr LLC

$1.49 Trillion
Q1 2025

A detailed history of Fmr LLC transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Fmr LLC holds 127,174 shares of PBYI stock, worth $429,848. This represents 0.0% of its overall portfolio holdings.

Number of Shares

127,174

Previous 131,850 3.55%

Holding current value

$429,848

Previous $402,000 6.47%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$2.76 - $3.88 $12,905 - $18,142	-4,676 Reduced 3.55%	127,174 $376,000
Q4 2024 Feb 13, 2025	BUY	$2.42 - $3.39 $32,875 - $46,053	13,585 Added 11.49%	131,850 $402,000
Q3 2024 Nov 13, 2024	BUY	$2.25 - $4.03 $56,661 - $101,487	25,183 Added 27.05%	118,265 $301,000
Q2 2024 Aug 13, 2024	BUY	$2.92 - $5.83 $4,064 - $8,115	1,392 Added 1.52%	93,082 $303,000
Q1 2024 May 13, 2024	BUY	$4.29 - $7.4 $152,792 - $263,558	35,616 Added 63.52%	91,690 $485,000
Q4 2023 Feb 13, 2024	SELL	$2.23 - $4.49 $18,520 - $37,289	-8,305 Reduced 12.9%	56,074 $242,000
Q3 2023 Nov 13, 2023	BUY	$2.63 - $4.09 $1,212 - $1,885	461 Added 0.72%	64,379 $169,000
Q2 2023 Aug 11, 2023	SELL	$2.6 - $3.58 $7 - $10	-3 Reduced -0.0%	63,918 $225,000
Q1 2023 May 11, 2023	BUY	$2.21 - $4.82 $26 - $57	12 Added 0.02%	63,921 $197,000
Q4 2022 Feb 13, 2023	SELL	$2.12 - $5.08 $852 - $2,042	-402 Reduced 0.63%	63,909 $270,000
Q3 2022 Nov 10, 2022	SELL	$2.27 - $3.84 $985 - $1,666	-434 Reduced 0.67%	64,311 $152,000
Q2 2022 Aug 12, 2022	BUY	$1.64 - $3.3 $86 - $174	53 Added 0.08%	64,745 $184,000
Q1 2022 May 13, 2022	BUY	$2.13 - $3.24 $137,793 - $209,602	64,692 New	64,692 $186,000

Others Institutions Holding PBYI

# of Institutions

116

Shares Held

30.9M

Call Options Held

32.7K

Put Options Held

200

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $154M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account